17549584. EFFECTS OF LGM2605 ON A PRIMATE MODEL OF ASTHMA simplified abstract (The Regents of the University of California)
Contents
- 1 EFFECTS OF LGM2605 ON A PRIMATE MODEL OF ASTHMA
- 1.1 Organization Name
- 1.2 Inventor(s)
- 1.3 EFFECTS OF LGM2605 ON A PRIMATE MODEL OF ASTHMA - A simplified explanation of the abstract
- 1.4 Simplified Explanation
- 1.5 Potential Applications
- 1.6 Problems Solved
- 1.7 Benefits
- 1.8 Potential Commercial Applications
- 1.9 Possible Prior Art
- 1.10 Unanswered Questions
- 1.11 Original Abstract Submitted
EFFECTS OF LGM2605 ON A PRIMATE MODEL OF ASTHMA
Organization Name
The Regents of the University of California
Inventor(s)
Melpo Christofidou-solomidou of Eagleville PA (US)
Angela Haczku of Davis CA (US)
EFFECTS OF LGM2605 ON A PRIMATE MODEL OF ASTHMA - A simplified explanation of the abstract
This abstract first appeared for US patent application 17549584 titled 'EFFECTS OF LGM2605 ON A PRIMATE MODEL OF ASTHMA
Simplified Explanation
The invention provides compositions and methods for treating asthma in a subject in need thereof by administering chemically synthesized secoisolariciresinol diglucoside (SDG), including a racemic mixture of SDG (LGM2605), stereoisomers, metabolites, and analogs. Additionally, methods for treating or preventing ozone-induced damage in a subject are also provided.
- Chemically synthesized secoisolariciresinol diglucoside (SDG) is used to treat asthma.
- The invention includes a racemic mixture of SDG (LGM2605), stereoisomers, metabolites, and analogs.
- Methods for treating or preventing ozone-induced damage in a subject are also provided.
Potential Applications
The technology can be applied in the pharmaceutical industry for the development of new asthma treatments. It can also be used in the field of environmental health to protect individuals from ozone-induced damage.
Problems Solved
This technology addresses the need for more effective treatments for asthma and provides a solution for preventing ozone-induced damage in individuals.
Benefits
The benefits of this technology include improved asthma treatment options, protection against ozone-induced damage, and potentially enhanced overall respiratory health for individuals.
Potential Commercial Applications
The technology has potential commercial applications in the pharmaceutical industry for the development of new asthma medications and in the environmental health sector for products aimed at protecting individuals from ozone-induced damage.
Possible Prior Art
One possible prior art could be the use of natural secoisolariciresinol diglucoside (SDG) extracted from flaxseed for various health benefits, including potential respiratory health effects. However, the chemically synthesized form and specific applications described in this patent application may represent a novel approach.
Unanswered Questions
1. What specific dosages and administration methods are recommended for the chemically synthesized secoisolariciresinol diglucoside (SDG) in treating asthma and preventing ozone-induced damage? 2. Are there any potential side effects or contraindications associated with the use of SDG in these applications that need to be further explored?
Original Abstract Submitted
The invention provides compositions and methods for treating asthma in a subject in need thereof comprising administering chemically synthesized secoisolaricirecinol diglucoside (SDG), and in particular, a racemic mixture of the SDG (LGM2605), stereoisomers thereof, metabolites thereof, and analogs thereof. Also provided are methods for treating or preventing ozone-induced damage in a subject in need thereof.
